This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Shareholders Of Acura Pharmaceuticals, Inc.

Law Offices of Howard G. Smith announces that it is investigating potential claims against Acura Pharmaceuticals, Inc. (“Acura Pharmaceuticals” or the “Company”) (NASDAQ:ACUR) concerning possible breaches of fiduciary duty or other violations of law by the Company’s board of directors. Acura Pharmaceuticals is a specialty pharmaceutical company, which engages in the research, development and manufacture of pharmaceutical product candidates utilizing the Company’s proprietary Aversion Technology, Impede Technology, and other technologies to provide abuse-deterrent features to tranquillizers, stimulants, sedatives, opioid analgesics and various other orally administered pharmaceutical drug products containing abusable active ingredients.

The investigation concerns allegations contained in a securities class action lawsuit filed September 10, 2010, in the United States District Court for the Northern District of Illinois. The lawsuit alleges that the Company and certain of its executive officers misrepresented or failed to disclose material adverse information concerning the efficacy of the Company’s lead product candidate, Acurox, and the drug’s prospects for approval by the U.S. Food and Drug Administration (“FDA”). Acurox is an orally administered immediate release analgesic containing oxycodone HCl as its active ingredient. On April 20, 2010, the FDA posted on its website briefing materials for an April 22, 2010, meeting to consider the New Drug Application of Acurox advising that, among other things, the Company’s Aversion Technology was not effective enough to warrant FDA approval, that its clinical studies were not properly designed and its clinical data defective, and that the Company had ignored directives from FDA as to specific clinical trials and evidence needed to demonstrate the safety and efficacy of Acurox.

If you purchased the securities of Acura Pharmaceuticals before 2006 through the present and still hold those shares, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ACUR $0.75 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs